1. |
Egwuagu CE, Alhakeem SA, Mbanefo EC. Uveitis: molecular pathogenesis and emerging therapies[J/OL]. Front Immunol, 2021, 12: 623725[2021-04-30]. https://pubmed.ncbi.nlm.nih.gov/33995347/. DOI: 10.3389/fimmu.2021.623725.
|
2. |
Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions[J]. Immunity, 2015, 43(6): 1040-1051. DOI: 10.1016/j.immuni.2015.12.003.
|
3. |
Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases[J]. Semin Immunopathol, 2019, 41(3): 283-297. DOI: 10.1007/s00281-019-00733-8.
|
4. |
Zhong Z, Su G, Kijlstra A, et al. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis[J/OL]. Prog Retin Eye Res, 2021, 80: 100866[2020-05-16]. https://pubmed.ncbi.nlm.nih.gov/32422390/. DOI: 10.1016/j.preteyeres.2020.100866.
|
5. |
Silver PB, Horai R, Chen J, et al. Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis[J]. J Immunol, 2015, 194(7): 3011-3019. DOI: 10.4049/jimmunol.1402650.
|
6. |
Eggenhuizen PJ, Ng BH, Ooi JD. Treg enhancing therapies to treat autoimmune diseases[J/OL]. Int J Mol Sci, 2020, 21(19): 7015[2020-09-23]. https://pubmed.ncbi.nlm.nih.gov/32977677/. DOI: 10.3390/ijms21197015.
|
7. |
Zhang L, Wan F, Song J, et al. Imbalance between Th17 cells and regulatory T cells during monophasic experimental autoimmune uveitis[J]. Inflammation, 2016, 39(1): 113-122. DOI: 10.1007/s10753-015-0229-7.
|
8. |
Chen YH, Lightman S, Calder VL. CD4(+) T-cell plasticity in non-infectious retinal inflammatory disease[J/OL]. Int J Mol Sci, 2021, 22(17): 9584[2021-09-03]. https://pubmed.ncbi.nlm.nih.gov/34502490/. DOI: 10.3390/ijms22179584.
|
9. |
Wu B, Wan Y. Molecular control of pathogenic Th17 cells in autoimmune diseases[J/OL]. Int Immunopharmacol, 2020, 80: 106187[2020-01-10]. https://www.ncbi.nlm.nih.gov/pubmed/31931372. DOI: 10.1016/j.intimp.2020.106187.
|
10. |
Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing[J]. Nat Rev Immunol, 2014, 14(9): 585-600. DOI: 10.1038/nri3707.
|
11. |
Ahern PP, Schiering C, Buonocore S, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells[J]. Immunity, 2010, 33(2): 279-288. DOI: 10.1016/j.immuni.2010.08.010.
|
12. |
Mohammadi FS, Aslani S, Mostafaei S, et al. Are genetic variations in IL-21-IL-23R-IL-17A cytokine axis involved in a pathogenic pathway of rheumatoid arthritis? Bayesian hierarchical meta-analysis[J]. J Cell Physiol, 2019, 234(10): 17159-17171. DOI: 10.1002/jcp.28495.
|
13. |
Wang C, Wang L, Hu J, et al. Increased expression of IL-23 receptor (IL-23R) in Vogt-Koyanagi-Harada (VKH) disease[J]. Curr Eye Res, 2018, 43(11): 1369-1373. DOI: 10.1080/02713683.2018.1485952.
|
14. |
Bose T, Diedrichs-Möhring M, Wildner G. Dry eye disease and uveitis: a closer look at immune mechanisms in animal models of two ocular autoimmune diseases[J]. Autoimmun Rev, 2016, 15(12): 1181-1192. DOI: 10.1016/j.autrev.2016.09.001.
|
15. |
Zhang Z, Xue Z, Liu Y, et al. MicroRNA-181c promotes Th17 cell differentiation and mediates experimental autoimmune encephalomyelitis[J]. Brain Behav Immun, 2018, 70: 305-314. DOI: 10.1016/j.bbi.2018.03.011.
|
16. |
Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates Th17 differentiation and is associated with the pathogenesis of multiple sclerosis[J]. Nat Immunol, 2009, 10(12): 1252-1259. DOI: 10.1038/ni.1798.
|
17. |
Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse[J/OL]. Curr Protoc Immunol, 2003, chapter 15: unit 15[2003-05-01]. https://pubmed.ncbi.nlm.nih.gov/18432901/. DOI: 10.1002/0471142735.im1506s53.
|
18. |
Zhang S, Yu N, Zhang R, et al. Interleukin-17A induces IL-1beta secretion from RPE cells via the NLRP3 Inflammasome[J]. Invest Ophthalmol Vis Sci, 2016, 57(2): 312-319. DOI: 10.1167/iovs.15-17578.
|
19. |
Chen Y, Yang P, Li F, et al. The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells[J/OL]. PLoS One, 2011, 6(3): e18139[2021-03-30]. https://pubmed.ncbi.nlm.nih.gov/21479174/. DOI: 10.1371/journal.pone.0018139.
|
20. |
Caspi RR. A look at autoimmunity and inflammation in the eye[J]. J Clin Invest, 2010, 120(9): 3073-3083. DOI: 10.1172/JCI42440.
|
21. |
Wei Y, Chen S, Sun D, et al. miR-223-3p promotes autoreactive Th17 cell responses in experimental autoimmune uveitis (EAU) by inhibiting transcription factor FOXO3 expression[J]. FASEB J, 2019, 33(12): 13951-13965. DOI: 10.1096/fj.201901446R.
|
22. |
Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: current and possible future therapies[J]. Inflamm Res, 2020, 69(5): 463-480. DOI: 10.1007/s00011-020-01339-9.
|
23. |
Neurath MF. IL-23: a master regulator in Crohn disease[J]. Nat Med, 2007, 13(1): 26-28. DOI: 10.1038/nm0107-26.
|
24. |
Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation[J]. J Exp Med, 2005, 201(2): 233-240. DOI: 10.1084/jem.20041257.
|
25. |
Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, et al. Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: a comprehensive review[J]. J Immunotoxicol, 2016, 13(3): 286-300. DOI: 10.3109/1547691X.2015.1115448.
|
26. |
Qian C, Jiang T, Zhang W, et al. Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis[J]. Cytokine, 2013, 64(1): 172-180. DOI: 10.1016/j.cyto.2013.07.005.
|
27. |
Milone MC, O'doherty U. Clinical use of lentiviral vectors[J]. Leukemia, 2018, 32(7): 1529-1541. DOI: 10.1038/s41375-018-0106-0.
|
28. |
Lamsfus-Calle A, Daniel-Moreno A, Urena-Bailen G, et al. Hematopoietic stem cell gene therapy: the optimal use of lentivirus and gene editing approaches[J/OL]. Blood Rev, 2020, 40: 100641[2019-11-15]. https://pubmed.ncbi.nlm.nih.gov/31761379/. DOI: 10.1016/j.blre.2019.100641.
|
29. |
Lee Y, Mitsdoerffer M, Xiao S, et al. IL-21R signaling is critical for induction of spontaneous experimental autoimmune encephalomyelitis[J]. J Clin Invest, 2015, 125(11): 4011-4020. DOI: 10.1172/JCI75933.
|
30. |
Dai H, He F, Tsokos GC, et al. IL-23 limits the production of IL-2 and promotes autoimmunity in lupus[J]. J Immunol, 2017, 199(3): 903-910. DOI: 10.4049/jimmunol.1700418.
|
31. |
Schmidt T, Paust HJ, Krebs CF, et al. Function of the Th17/interleukin-17A immune response in murine lupus nephritis[J]. Arthritis Rheumatol, 2015, 67(2): 475-487. DOI: 10.1002/art.38955.
|
32. |
Wu C, Chen Z, Xiao S, et al. SGK1 governs the reciprocal development of Th17 and regulatory T cells[J]. Cell Rep, 2018, 22(3): 653-665. DOI: 10.1016/j.celrep.2017.12.068.
|